Financing ·
On August 27, 2026, Cero Therapeutics Holdings completed a secured financing transaction with SRX Global Inc., issuing…
CEROCero Therapeutics Holdings, Inc.
On August 27, 2026, Cero Therapeutics Holdings completed a secured financing transaction with SRX Global Inc., issuing a Consolidated Senior Secured Promissory Note. This note consolidates $5,666,108.77 in previous unsecured debt held by SRX and Keystone Capital Partners into a single secured obligation. The agreement allows for additional advances up to $6,000,000, bringing the maximum aggregate loan amount to $11,666,108.77. An initial advance of $775,665 was funded on the execution date, net of a $50,000 legal fee reimbursement. The note bears interest at 10% per annum, increasing to 24.99% upon default, with principal due by October 15, 2026. SRX holds a first-priority security interest in the subsidiary's capital stock and assets, including intellectual property related to CER-1236. The company operates in the biotechnology industry, focusing on cell therapy treatments.